Cancer and scleroderma: A paraneoplastic disease with implications for malignancy screening

Current Opinion in Rheumatology

Volumn 27, Issue 6, 2015, Pages 563-570

  Shah, Ami A ^a,b   Casciola Rosen, Livia ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer; Paraneoplastic; Scleroderma

Indexed keywords

DNA DIRECTED RNA POLYMERASE III;

CANCER RISK; CANCER SCREENING; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCLERODERMA; SOMATIC MUTATION; COMPLICATION; EARLY CANCER DIAGNOSIS; NEOPLASMS; PARANEOPLASTIC SYNDROMES; SCLERODERMA, SYSTEMIC;

EARLY DETECTION OF CANCER; HUMANS; NEOPLASMS; PARANEOPLASTIC SYNDROMES; SCLERODERMA, SYSTEMIC;

EID: 84942516395     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000222     Document Type: Review

References (49)

1. Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheumat 1993; 36:460-464.
2. Bonifazi M, Tramacere I, Pomponio G, et al. Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology 2013; 52:143-154.
3. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006; 33:1113-1116.
4. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003; 62:728-731.
5. Kuo CF, Luo SF, Yu KH, et al. Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 2012; 41:44-49.
6. Olesen AB, Svaerke C, Farkas DK, Sorensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 2010; 163:800-806.
7. Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheumat 2013; 65:1913-1921.
8. Rosenthal AK, McLaughlin JK, Gridley G, Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995; 76:910-914.
9. Siau K, Laversuch CJ, Creamer P, O'Rourke KP. Malignancy in scleroderma patients from south west England: a population-based cohort study. Rheumatol Int 2011; 31:641-645.
10. Zhang JQ, Wan YN, Peng WJ, et al. The risk of cancer development in systemic sclerosis: a meta-analysis. Cancer Epidemiol 2013; 37:523-527.
11. Forbes AM, Woodrow JC, Verbov JL, Graham RM. Carcinoma of breast and scleroderma: four further cases and a literature review. Br J Rheumatol 1989; 28:65-69.
12. Launay D, Le Berre R, Hatron PY, et al. Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. Clin Rheumatol 2004; 23:516-522.
13. Derk CT, Rasheed M, Spiegel JR, Jimenez SA. Increased incidence of carcinoma of the tongue in patients with systemic sclerosis. J Rheumatol 2005; 32:637-641.
14. Kang KY, Yim HW, Kim IJ, et al. Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumat 2009; 38:299-303.
15. Peters-Golden M, Wise RA, Hochberg M, et al. Incidence of lung cancer in systemic sclerosis. J Rheumatol 1985; 12:1136-1139.
16. Nikpour M, Hissaria P, Byron J, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: across-section alanalysis of data from an Australian cohort. Arthritis Res Ther 2011; 13:R211.
17. Shah AA, Hummers LK, Casciola-Rosen L, et al. Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis & Rheumatol 2015; 67:1053-1061.
18. Shah AA, Rosen A. Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications. Curr Opin Rheumatol 2011; 23:530-535.
19. Wipff J, Allanore Y, Soussi F, et al. Prevalence of Barrett's esophagus in systemic sclerosis. Arthritis Rheum 2005; 52:2882-2888.
20. Cavazza A, Caballeria L, Floreani A, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 2009; 50:1162-1168.
21. Trivedi PJ, Lammers WJ, van Buuren HR, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut 2015.
22. Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008; 35:100-105.
23. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum 2010; 62:9-21.
24. Bichari W, Bartiromo M, Mohey H, et al. Significant risk factors for occurrence of cancer after renal transplantation: a single center cohort study of 1265 cases. Transplant Proc 2009; 41:672-673.
25. Brewer JD, Colegio OR, Phillips PK, et al. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol 2009; 145:1391-1396.
26. Marcen R, Galeano C, Fernandez-Rodriguez A, et al. Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation. Transplant Proc 2010; 42:3055-3057.
27. Robson R, Cecka JM, Opelz G, et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5:2954-2960.
28. Berger CC, Bokemeyer C, Schneider M, et al. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 1995; 31A:2229-2238.
29. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol 2004; 51 (2 Suppl):S73-S76.
30. Clowse ME, Wigley FM. Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. J Rheumatol 2003; 30:1341-1343.
31. Cohen IS, Mosher MB, O'Keefe EJ, et al. Cutaneous toxicity of bleomycin therapy. Arch Dermatol 1973; 107:553-555.
32. De Angelis R, Bugatti L, Cerioni A, et al. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clin Rheumatol 2003; 22:49-52.
33. Finch WR, Rodnan GP, Buckingham RB, et al. Bleomycin-induced scleroderma. J Rheumatol 1980; 7:651-659.
34. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000;43:1431-1442.
35. Abu-Shakra M, Lee P. Exaggerated fibrosis in patients with systemic sclerosis (scleroderma) following radiation therapy. J Rheumatol 1993; 20:1601-1603.
36. Colver GB, Rodger A, Mortimer PS, et al. Postirradiation morphoea. Br J Dermatol 1989; 120:831-835.
37. Varga J, Haustein UF, Creech RH, et al. Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA 1991; 265:3292-3295.
38. Lacasse Y, Martin S, Gagne D, Lakhal L. Dose-response meta-analysis of silica and lung cancer. Cancer Causes Control 2009; 20:925-933.
39. McCormic ZD, Khuder SS, Aryal BK, et al. Occupational silica exposure as a risk factor for scleroderma: a meta-analysis. Int Arch Occup Environ Health 2010; 83:763-769.
40. Shah AA, Rosen A, Hummers L, et al. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheumat 2010; 62:2787-2795.
41. Airo P, Ceribelli A, Cavazzana I, et al. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 2011; 38:1329-1334.
42. Moinzadeh P, Fonseca C, Hellmich M, et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 2014; 16:R53.
43. Shah AA, Casciola-Rosen L, Rosen A. Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol 2015; 67:317-326.
44. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 2014; 343:152-157.
45. Lin RH, Mamula MJ, Hardin JA, Janeway CA Jr. Induction of autoreactive B cells allows priming of autoreactive T cells. J Exp Med 1991; 173:1433-1439.
46. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009; 50:291-308.
47. National Lung Screening Trial Research T. Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. New Engl J Med 2011; 365:395-409.
48. Sawaya GF, Kulasingam S, Denberg T, Qaseem A. Cervical cancer screening in average-risk women: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2015; 162:851-859.
49. Shaheen NJ, Weinberg DS, Denberg TD, et al. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2012; 157:808-816.